Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000116.xml
Download PDF
Semin Vasc Med 2002; 2(1): 075-086
DOI: 10.1055/s-2002-23098
DOI: 10.1055/s-2002-23098
Coagulation and Fibrinolysis in Diabetes
Further Information
Publication History
Publication Date:
25 March 2002 (online)
ABSTRACT
The accelerated development of atherothrombotic cardiovascular disease in type 2 diabetes mellitus may be enhanced by the presence of a prothrombotic state. This prothrombotic state includes a diminished fibrinolytic capacity and an increased coagulability. Impaired fibrinolytic capacity appears to be a hallmark of the metabolic syndrome of type 2 diabetes and can be a direct consequence of visceral obesity. In addition, a chronic low inflammatory state with hyperinsulinemia and dyslipidemia may further influence the hemostatic balance. The characteristic dyslipidemia of type 2 diabetes, coined the atherogenic lipoprotein profile, with raised plasma levels of fasting and postprandial triglyceride lipoproteins, atherogenic low-density lipoproteins, and low high-density lipoproteins, is involved in promoting a hypercoagulable state. Lifestyle and pharmacologic interventions that reduce cardiovascular risk in the general population and that may improve the metabolic syndrome may also reduce the prothrombotic state.
KEYWORD
Metabolic syndrome - type 2 diabetes - fibrinolysis - coagulation - dyslipidemia
REFERENCES
- 1 Davies M J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation . 1996; 94(8) 2013-2020
- 2 Farb A, Burke A P, Tang A L. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation . 1996; 93(7) 1354-1363
- 3 Falk E, Shah P K, Fuster V. Coronary plaque disruption. Circulation . 1995; 92(3) 657-671
- 4 Schneiderman J, Sawdey M S, Keeton M R. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA . 1992; 89(15) 6998-7002
- 5 Lupu F, Bergonzelli G E, Heim D A. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb . 1993; 13(7) 1090-1100
- 6 Fernandez-Ortiz A, Badimon J J, Falk E. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol . 1994; 23(7) 1562-1569
- 7 Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis . 1992; 94(2-3) 93-107
- 8 Banga J D, Sixma J J. Diabetes mellitus, vascular disease and thrombosis. Clin Haematol . 1986; 15(2) 465-492
- 9 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med . 1999; 340(20) 1555-1564
- 10 Kullo I J, Gau G T, Tajik A J. Novel risk factors for atherosclerosis. Mayo Clin Proc . 2000; 75(4) 369-380
- 11 Folsom A R. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost . 2001; 86(1) 366-373
- 12 Poli K A, Tofler G H, Larson M G. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation . 2000; 101(3) 264-269
- 13 Newby D E, Wright R A, Labinjoh C. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation . 1999; 99(11) 1411-1415
- 14 Yudkin J S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?. Diabetes Care . 1999; 22 (suppl 3) C25-C30
- 15 Baldeweg S E, Pink A M, Yudkin J S, Coppack S W. The relationship between obesity, vascular reactivity and endothelial dysfunction in subjects with non-insulin dependent diabetes mellitus. Int J Obes Relat Metab Disord . 2000; 24 (suppl 2) S134-S135
- 16 Fujii S, Goto D, Zaman T. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. J Atheroscler Thromb . 1998; 5(2) 76-81
- 17 Alessi M C, Morange P, Juhan-Vague I. Fat cell function and fibrinolysis. Horm Metab Res . 2000; 32(11-12) 504-508
- 18 Hsueh W A, Law R E. Insulin signaling in the arterial wall. Am J Cardiol . 1999; 84(1A) 21J-24J
- 19 Juhan-Vague I, Alessi M C, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med . 1996; 28(4) 371-380
- 20 McGill J B, Schneider D J, Arfken C L, Lucore C L, Sobel B E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes . 1994; 43(1) 104-109
- 21 Sobel B E. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians . 1999; 111(4) 313-318
- 22 Eliasson M, Asplund K, Evrin P E, Lindahl B, Lundblad D. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study. Metabolism . 1994; 43(12) 1579-1586
- 23 Juhan-Vague I, Thompson S G, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb . 1993; 13(12) 1865-1873
- 24 Juhan-Vague I, Pyke S D, Alessi M C, Jespersen J, Haverkate F, Thompson S G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation . 1996; 94(9) 2057-2063
- 25 Fattal P G, Schneider D J, Sobel B E, Billadello J J. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem . 1992; 267(18) 12412-12415
- 26 Sironi L, Mussoni L, Prati L. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol . 1996; 16(1) 89-96
- 27 Nordt T K, Klassen K J, Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb . 1993; 13(12) 1822-1828
- 28 Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis . 1988; 8(1) 68-72
- 29 Sobel B E. Insulin resistance and thrombosis: a cardiologist's view. Am J Cardiol . 1999; 84(1A) 37J-41J
- 30 Hamsten A, de Faire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet . 1987; 2(8549) 3-9
- 31 Jansson J H, Olofsson B O, Nilsson T K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation . 1993; 88(5 Pt 1) 2030-2034
- 32 Zalewski A, Shi Y, Nardone D. Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates. Circulation . 1991; 83(5) 1685-1691
- 33 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med . 1985; 313(25) 1557-1563
- 34 Hoffmeister H M, Jur M, Ruf-Lehmann M, Helber U, Heller W, Seipel L. Endothelial tissue-type plasminogen activator release in coronary heart disease: transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol . 1998; 31(3) 547-551
- 35 Meade T W, Ruddock V, Stirling Y, Chakrabarti R, Miller G J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet . 1993; 342(8879) 1076-1079
- 36 Scarabin P Y, Aillaud M F, Amouyel P. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction-the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost . 1998; 80(5) 749-756
- 37 Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein F W, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost . 1999; 82(3) 1121-1126
- 38 Ridker P M, Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet . 1993; 341(8854) 1165-1168
- 39 Lowe G D, Yarnell J W, Sweetnam P M, Rumley A, Thomas H F, Elwood P C. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost . 1998; 79(1) 129-133
- 40 Hoffmeister H M, Jur M, Wendel H P, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation . 1995; 91(10) 2520-2527
- 41 Anderson J L, Muhlestein J B, Habashi J. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol . 1999; 34(6) 1778-1783
- 42 Rallidis L S, Megalou A A, Papageorgakis N H, Trikas A G, Chatzidimitriou G I, Tsitouris G K. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction. Thromb Haemost . 1996; 76(3) 417-421
- 43 Bara L, Nicaud V, Tiret L, Cambien F, Samama M M. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring-the EARS study. European Atherosclerosis Research Study Group. Thromb Haemost . 1994; 71(4) 434-440
- 44 Di Minno G, Coppola A, Mancini F P, Margaglione M. Homocysteine, platelet function and thrombosis. Haematologica . 1999; 84 61-63
- 45 Roest M, van der Schouw T Y, Banga J D. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation . 2000; 101(1) 67-70
- 46 Hantgan R R, Jerome W G, Handt S. Platelets and endothelial cells act in concert to delay thrombolysis-evidence from an in vitro model of the human occlusive thrombus. Thromb Haemost . 1998; 79(3) 602-608
- 47 Robbie L A, Booth N A, Brown A J, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol . 1996; 16(4) 539-545
- 48 Sobel B E, Woodcock-Mitchell J, Schneider D J, Holt R E, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation . 1998; 97(22) 2213-2221
- 49 Fukao H, Matsuo O. Antithrombotic regulation in human endothelial cells by fibrinolytic factors. Semin Thromb Hemost . 2000; 26(1) 33-38
- 50 Marx N, Bourcier T, Sukhova G K, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol . 1999; 19(3) 546-551
- 51 Zhu Y, Carmeliet P, Fay W P. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation . 1999; 99(23) 3050-3055
- 52 Sprengers E D, Kluft C. Plasminogen activator inhibitors. Blood . 1987; 69(2) 381-387
- 53 Hajjar K A, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med . 1999; 9(5) 128-138
- 54 Hajjar K A, Gavish D, Breslow J L, Nachman R L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature . 1989; 339(6222) 303-305
- 55 Hajjar K A, Jacovina A T. Modulation of annexin II by homocysteine: implications for atherothrombosis. J Investig Med . 1998; 46(8) 364-369
- 56 Sayer J W, Gutteridge C, Syndercombe-Court D, Wilkinson P, Timmis A D. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. J Am Coll Cardiol . 1998; 32(7) 1962-1968
- 57 Sobel B E. Coronary artery disease and fibrinolysis: from the blood to the vessel wall. Thromb Haemost . 1999; 82 (suppl 1) 8-13
- 58 Skrha J, Hodinar A, Kvasnicka J, Hilgertova J. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet Med . 1996; 13(9) 800-805
- 59 Juhan-Vague I, Renucci J F, Grimaux M. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol . 2000; 20(9) 2156-2161
- 60 Killewich L A, Gardner A W, Macko R F. Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg . 1998; 27(4) 645-650
- 61 Killewich L A, Macko R F, Gardner A W, Cox K, Lilly M P, Flinn W R. Defective fibrinolysis occurs after infrainguinal reconstruction. J Vasc Surg . 1997; 25(5) 858-864
- 62 Mussoni L, Mannucci L, Sirtori M. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb . 1992; 12(1) 19-27
- 63 Mehrabian M, Peter J B, Barnard R J, Lusis A J. Dietary regulation of fibrinolytic factors. Atherosclerosis . 1990; 84(1) 25-32
- 64 Svendsen O L, Hassager C, Christiansen C, Nielsen J D, Winther K. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol . 1996; 16(3) 381-385
- 65 Toft I, Bonaa K H, Ingebretsen O C, Nordoy A, Jenssen T. Fibrinolytic function after dietary supplementation with omega-3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol . 1997; 17(5) 814-819
- 66 Speiser W, Langer W, Pschaick A. Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb Res . 1988; 51(5) 543-555
- 67 Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J . 1998; 19 (suppl C) C39-C43
- 68 Fuller J H, McCartney P, Jarrett R J. Hyperglycaemia and coronary heart disease: the Whitehall Study. J Chronic Dis . 1979; 32(11-12) 721-728
- 69 Ford I, Singh T P, Kitchen S, Makris M, Ward J D, Preston F E. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med . 1991; 8(4) 322-329
- 70 Lowe G D, Ghafour I M, Belch J J, Forbes C D, Foulds W S, MacCuish A C. Increased blood viscosity in diabetic proliferative retinopathy. Diabetes Res . 1986; 3(2) 67-70
- 71 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA . 1998; 279(18) 1477-1482
- 72 Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol . 1999; 19(6) 1368-1377
- 73 Morishita E, Asakura H, Jokaji H. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis . 1996; 120(1-2) 7-14
- 74 Morrow D A, Ridker P M. C-reactive protein, inflammation, and coronary risk. Med Clin North Am . 2000; 84(1) 149-161
- 75 Packard C J, O'Reilly D S, Caslake M J. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med . 2000; 343(16) 1148-1155
- 76 Lijnen H R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost . 2001; 86(1) 324-333
- 77 Cooper J A, Miller G J, Bauer K A. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation . 2000; 102(23) 2816-2822
- 78 Urbich C, Walter D H, Zeiher A M, Dimmeler S. Laminar shear stress upregulates integrin expression: role in endothelial cell adhesion and apoptosis. Circ Res . 2000; 87(8) 683-689
- 79 Kohler H P, Grant P J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med . 2000; 342(24) 1792-1801
- 80 de Lange M, Snieder H, Ariens R A, Spector T D, Grant P J. The genetics of haemostasis: a twin study. Lancet . 2001; 357(9250) 101-105
- 81 Simmonds R E, Hermida J, Rezende S M, Lane D A. Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost . 2001; 86(1) 374-385
- 82 Warner D, Mansfield M W, Grant P J. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography. Thromb Haemost . 2001; 85(3) 408-411
- 83 Ruggeri Z M, Ware J. The structure and function of von Willebrand factor. Thromb Haemost . 1992; 67(6) 594-599
- 84 Jager A, van Hinsbergh W V, Kostense P J. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol . 1999; 19(12) 3071-3078
- 85 Kanters S D, Banga J D, Algra A, Frijns R C, Beutler J J, Fijnheer R. Plasma levels of cellular fibronectin in diabetes. Diabetes Care . 2001; 24(2) 323-327
- 86 Taubman M B, Giesen P L, Schecter A D, Nemerson Y. Regulation of the procoagulant response to arterial injury. Thromb Haemost . 1999; 82(2) 801-805
- 87
Zoldhelyi P, Chen Z Q, Shelat H S, McNatt J M, Willerson J T.
Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia
in atherosclerotic arteries.
Proc Natl Acad Sci USA .
2001;
98(7)
4078-4083
MissingFormLabel
- 88 de Jonge E, Dekkers P E, Creasey A A. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis . 2001; 183(12) 1815-1818
- 89 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ . 1994; 308(6921) 81-106
- 90 Bhatt D L, Topol E J. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am . 2000; 84(1) 163-79
- 91 Patrono C, Davi G. Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes Metab Rev . 1993; 9(3) 177-188
- 92 Jennings P E. From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease. J Diabetes Complications . 1994; 8(4) 226-230
- 93 Hendra T J, Oswald G A, Yudkin J S. Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Res Clin Pract . 1988; 5(1) 63-69
- 94 Gray R P, Hendra T J, Patterson D L, Yudkin J S. ``Spontaneous'' platelet aggregation in whole blood in diabetic and non diabetic survivors of acute myocardial infarction. Thromb Haemost . 1993; 70(6) 932-936
- 95 Hendra T J, Yudkin J S. ``Spontaneous'' platelet aggregation in whole blood in diabetic patients with and without microvascular disease. Diabet Med . 1992; 9(3) 247-251
- 96 Preston F E, Ward J D, Marcola B H, Porter N R, Timperley W R, O'Malley B C. Elevated beta-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet . 1978; 1(8058) 238-240
- 97 Wu K K, Hoak J C. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet . 1974; 2(7886) 924-926
- 98 Tschoepe D, Roesen P, Kaufmann L. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest . 1990; 20(2) 166-170
- 99 Watala C, Gwozdzinski K, Pluskota E. Diabetes mellitus alters the effect of peptide and protein ligands on membrane fluidity of blood platelets. Thromb Haemost . 1996; 75(1) 147-153
- 100 Watanabe J, Umeda F, Wasada T, Ibayashi H. Effect of prostaglandin synthetase inhibitors on platelet aggregation and thromboxane production in diabetes mellitus. Tohoku J Exp Med . 1984; 144(2) 143-150
- 101 Austin M A, King M C, Vranizan K M, Krauss R M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation . 1990; 82(2) 495-506
- 102 Rosenson R S, Lowe G D. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis . 1998; 140(2) 271-280
- 103 Griffin J H, Fernandez J A, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost . 2001; 86(1) 386-394
- 104 Bradley W A, Gianturco S H. Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin Thromb Hemost . 1988; 14(3) 253-257
- 105 de Sousa C J, Soria C, Ayrault-Jarrier M. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol . 1988; 41(9) 940-944
- 106 Silveira A, Karpe F, Blomback M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb . 1994; 14(1) 60-69
- 107 Moyer M P, Tracy R P, Tracy P B, van't Veer C, Sparks C E, Mann K G. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol . 1998; 18(3) 458-465
- 108 Rota S, McWilliam N A, Baglin T P, Byrne C D. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood . 1998; 91(2) 508-515
- 109 Xu N, Ohlin A K, Zhou L, Nilsson A. Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids. Thromb Res . 1995; 80(1) 35-46
- 110 Xu N, Dahlback B, Ohlin A K, Nilsson A. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol . 1998; 18(1) 33-39
- 111 Zhang J, Ren S, Sun D, Shen G X. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol . 1998; 18(7) 1140-1148
- 112 Franceschini G, Cofrancesco E, Safa O. Association of lipoprotein(a) with atherothrombotic events and fibrinolytic variables. A case-control study. Thromb Res . 1995; 78(3) 227-238
- 113 Tabengwa E M, Benza R L, Grenett H E, Booyse F M. Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells. Arterioscler Thromb Vasc Biol . 2000; 20(6) 1675-1681
- 114 Banfi C, Mussoni L, Ris P. Very low-density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res . 1999; 85(2) 208-217
- 115 Dichtl W, Stiko A, Eriksson P. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol . 1999; 19(12) 3025-3032
- 116 Pajkrt D, Lerch P G, van der Poll T. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost . 1997; 77(2) 303-307
- 117 Li D, Weng S, Yang B. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol . 1999; 19(2) 378-383
- 118 Naqvi T Z, Shah P K, Ivey P A. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol . 1999; 84(9) 1011-1017
- 119 Ishibashi S. Lipoprotein(a) and atherosclerosis. Arterioscler Thromb Vasc Biol . 2001; 21(1) 1-2
- 120 Harpel P C, Hermann A, Zhang X, Ostfeld I, Borth W. Lipoprotein(a), plasmin modulation, and atherogenesis. Thromb Haemost . 1995; 74(1) 382-386
- 121 Zhang J, Ren S, Shen G X. Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis . 2000; 150(2) 299-308
- 122 Lundstam U, Hurt-Camejo E, Olsson G, Sartipy P, Camejo G, Wiklund O. Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix. Arterioscler Thromb Vasc Biol . 1999; 19(5) 1162-1167
- 123 Karpe F. Mechanisms of postprandial hyperlipidaemia-remnants and coronary artery disease. Diabet Med . 1997; 14 (suppl 3) S60-S66
- 124 Moor E, Hamsten A, Karpe F, Bavenholm P, Blomback M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost . 1994; 71(6) 707-712
- 125 Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol . 1998; 18(1) 20-26
- 126 Broijersen A, Karpe F, Hamsten A, Goodall A H, Hjemdahl P. Alimentary lipemia enhances the membrane expression of platelet P- selectin without affecting other markers of platelet activation. Atherosclerosis . 1998; 137(1) 107-113
- 127 Silveira A, Karpe F, Johnsson H, Bauer K A, Hamsten A. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol . 1996; 16(11) 1333-1339
- 128 Miller G J. Lipoproteins and the haemostatic system in atherothrombotic disorders. Baillieres Best Pract Res Clin Haematol . 1999; 12(3) 555-575
- 129 Morishita E, Jokaji H, Matsuda T. Hyperlipidemia and hemostatic system. J Atheroscler Thromb . 1995; 2 (suppl 1) S36-S40
- 130 Byrne C D. Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?. Atherosclerosis . 1999; 145(1) 1-15